Skip to content

Study on the Application of ¹8F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases

Study on the Application of ¹8F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120067
Enrollment
Unknown
Registered
2026-03-09
Start date
2026-03-09
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurodegenerative diseases

Interventions

Patients with neurodegenerative diseases:Perform 18F-FCOB04 PET/CT or PET/MRI brain scan
Healthy Subject:Perform 18F-FCOB04 PET/CT or PET/MRI brain scan

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients 1. Aged between 18 and 75 years, regardless of gender. 2. Patients diagnosed with probable or possible neurodegenerative diseases by a specialist neurologist according to current internationally recognized clinical diagnostic criteria, including but not limited to Alzheimer’s disease, Parkinson’s disease, and Parkinsonian syndromes (such as progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, etc.).Diagnosis is based on a comprehensive evaluation including systematic medical history collection, neurological examination, relevant neuropsychological or motor function scale assessments, combined with conventional structural neuroimaging such as cranial MRI.Patients with a history of brain surgery, brain cyst, brain tumor, or other comorbidities that may affect data analysis are excluded. 3. Prior to any assessment, the subject or their legal representative has understood and signed the written informed consent form. 4. Subjects who are currently using, or have not used MAO-B inhibitors (including but not limited to selegiline, rasagiline, safinamide) for >=14 days prior to enrollment. Healthy Subject Inclusion Criteria: 1. Age: >=18 years, any gender; 2. Cognition deemed normal by the investigator through cognitive testing; 3. Confirmed by the investigator to have no neurological diseases, major chronic diseases, malignant tumors, or acute infectious diseases; 4. No family history of neurological diseases related to cognitive or motor disorders; 5. Understand and sign the written informed consent before undergoing any assessments.

Exclusion criteria

Exclusion criteria: 1. Suffering from other severe neurological diseases, or severe diseases of the gastrointestinal, cardiovascular, hepatic, renal, hematological, oncological, endocrine, respiratory, immunodeficiency or other severe systemic disorders. 2. Suffering from claustrophobia. 3. History of substance abuse or excessive alcohol consumption. 4. Female subjects who are pregnant or breastfeeding. 5. Presence of any condition that, in the opinion of the investigator, may be harmful or potentially harmful to the subject in any procedure related to this study.

Design outcomes

Primary

MeasureTime frame
Regional and extent differences in 18F-FCOB04 brain imaging uptake across various brain regions;

Countries

China

Contacts

Public ContactXianzhong Zhang

Peking Union Medical College Hospital

zhangxzh@pumch.cn+86 10 6915 4664

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026